Clinical Trials Browser

INDUSTRY × Metastatic Hormone-sensitive Prostate Cancer × Clear all

NCT06991556 2026-04-16

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 2 Recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT05901649 2026-04-13

ArtemisPRO

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 5 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Metastatic Hormone-sensitive Prostate Cancer